Trials / Completed
CompletedNCT05023928
Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer
Research on the Transformation of Postoperative Adjuvant Therapy of Tumor Antigen-sensitized DC Vaccine Applied to Esophagus Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Sichuan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-sensitized DC vaccine in postoperative adjuvant treatment of esophageal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tumor antigen-sensitized DC vaccine | subcutaneous administration |
Timeline
- Start date
- 2021-09-01
- Primary completion
- 2023-10-01
- Completion
- 2024-10-30
- First posted
- 2021-08-27
- Last updated
- 2025-03-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05023928. Inclusion in this directory is not an endorsement.